UK markets closed

Lattice Biologics Ltd. (LBLTF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
0.04500.0000 (0.00%)
At close: 9:30AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.0450
Open0.0450
Bid0.0000 x 0
Ask0.0000 x 0
Day's range0.0450 - 0.0450
52-week range0.0161 - 0.1025
Volume1,010
Avg. volume23,613
Market cap4.213M
Beta (5Y monthly)-12.08
PE ratio (TTM)N/A
EPS (TTM)-0.0150
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Lattice Announces Strategic Advisory Board

    Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: LBLTF) ("Lattice" or the "Company"), an emerging leader in psilocybin research and cannabis company, today announced the formation of its Strategic Advisory Board, a group of respected business leaders that will provide guidance to Lattice’s executive team as it continues to build and strengthen the Company's portfolio of cannabis and psilocybin related brands and products

  • Business Wire

    Lattice Announces Strategic Cannabis Supply Agreement With Firehouse

    Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: LBLTF) ("Lattice" or the "Company"), an emerging leader in psilocybin research and cannabis company, today announced it has entered into a Strategic Supply Agreement (the "Agreement") with Firehouse LLC ("Firehouse"), one of Montana’s most established medical cannabis producers.

  • Business Wire

    Lattice Biologics Reorganizes to Focus on Psychedelics and Cannabis Therapies

    Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: LBLTF) ("Lattice Biologics" or the "Company") announced today that the Company will change its business strategy to focus on the fast growing psychedelics and cannabis markets through the creation of a new life sciences subsidiary. The Company will focus on the research and commercialization of psychedelic products in combination with its stem cell based regenerative compounds while leveraging the Company’s distribution expertise.